Table 2 Correlations (r) between biomarker values at baseline for all patients and at week 24 for patients in the infliximab and placebo groups separately
VEGFTGF-βCTXOsteocalcinBAP
Baseline
    IL-60.264***0.1050.1120.0640.040
    VEGF0.256***0.0520.0140.084
    TGF-β0.0340.0890.148*
    CTX0.476***0.367***
    Osteocalcin0.336***
Week 24: infliximab
    IL-60.446***0.1230.035−0.268**−0.157*
    VEGF0.494***0.021−0.288**−0.148****
    TGF-β0.0740.0510.095
    CTX0.273**0.169*
    Osteocalcin0.391***
Week 24: placebo
    IL-6−0.019−0.0410.031−0.130−0.114
    VEGF0.564***0.102−0.0580.087
    TGF-β0.162−0.1210.071
    CTX0.259*−0.062
    Osteocalcin0.274*
  • BAP, bone alkaline phosphatase; CTX, C-terminal cross-linking telopeptide of type I collagen; IL-6, interleukin-6; TGF-β, transforming growth factor β; VEGF, vascular endothelial growth factor.

  • *p<0.05; **p<0.005; ***p<0.0001; ****p = 0.0513.